Read by QxMD icon Read

Preoperative chemotherapy of NSCLC

Cuiping Tang, Si Qin, Wanchun Wu, Yang Wu, Tao Zhang
BACKGROUND: The therapeutic effect and side effect of neoadjuvant chemotherapy were still disputing issues when applied to resectable IIIa stage non-small cell lung cancer (NSCLC) patients. The retrospective analysis was aimed to investigate the short-term efficacy and postoperative complications in resectable IIIa NSCLC patients treated with neoadjuvant chemotherapy. METHODS: According to inclusion criteria and exclusion criteria, 370 patients with clinical diagnosis of IIIa NSCLC were selected from our hospital between January 2011 and October 2013 were retrospectively analyzed...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
Nhu-Tram A Nguyen, Naghmeh Isfahanian, Gregory Pond, Wael Hanna, Jean-Claude Cutz, James Wright, Anand Swaminath, Yaron Shargall, Tom Chow, Marcin Wierzbicki, Gordon Okawara, Kimmen Quan, Christian Finley, Rosalyn Juergens, Theodoros Tsakiridis
BACKGROUND: Despite improved staging and surgical techniques, the rate of incomplete resection (R1) of non-small-cell lung cancer (NSCLC) has not significantly decreased. Patients with R1 resection have worse survival compared with those with complete resection (R0). Stereotactic body radiotherapy (SBRT) is a rapid and convenient radiotherapy treatment that delivers high-dose radiotherapy to tumors with high precision while sparing normal organs. Although its efficacy in treating small lung tumors is documented, its use as neoadjuvant therapy for locally advanced (LA) NSCLC has not been examined...
January 31, 2017: Clinical Lung Cancer
Anne-Marie Ruppert, Armelle Lavolé, Jalal Assouad, Jacques Cadranel, Marie Wislez
Platinum-based perioperative chemotherapy is actually the standard of care in stage II-IIIa non-small cell lung cancer (NSCLC). A benefit may also be seen in stage IB NSCLC with tumors of more than 4cm of diameter. Perioperative chemotherapy improves 5-year survival of 4 to 15%. This benefit is mainly proved by postoperative chemotherapy trials. Nevertheless, preoperative chemotherapy has advantages: a better tolerance, an estimation of tumor chemosensibility, without an increased postoperative morbimortality...
January 2017: Bulletin du Cancer
Masafumi Yamaguchi, Makoto Edagawa, Yuzo Suzuki, Ryo Toyozawa, Fumihiko Hirai, Kaname Nosaki, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose
BACKGROUND: We wanted to assess the efficacy of curative intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with synchronous M1b-distant metastases in a single organ or lesion. METHODS: Between 1995 and 2015, 23 consecutive synchronous M1b-cStage IV NSCLC patients who underwent any treatment for metastases and curative intent pulmonary resection were retrospectively analyzed. RESULTS: Sixteen patients were men and 7 were women, with a median age of 56 years (range: 41 to 76 years)...
November 15, 2016: Annals of Thoracic Surgery
Rachel C Numan, Martijn Ten Berge, Jacobus A Burgers, Houke M Klomp, Johanna W van Sandick, Paul Baas, Michel W Wouters
Identification of evidenced-based Quality of Care (QoC) indicators for lung cancer care is essential to quality improvement. The aim of this review was to identify evidence-based quality indicators for the pre- and postoperative care of stage I-III Non Small Cell Lung Cancer (NSCLC) provided by the lung physician. To obtain these indicators, a search in PubMed, Embase and the Cochrane library database was performed. English literature published between 1980 and 2012 was included and search terms regarding 'lung neoplasms', 'quality of care', 'pathology', 'diagnostic methods', 'preoperative and postoperative treatment' were used...
November 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Shan Xian Guo, Yan Jian, Ying Lan Chen, Yun Cai, Qing Yuan Zhang, Fang Fang Tou
Neoadjuvant Chemotherapy has been used for the stage III of non-small cell lung cancer (NSCLC) and has shown good clinical effects. However, the survival benefits of radiation therapy added in induction regimens remains controversial. We therefore conducted a meta-analysis of the published clinical trials to quantitatively evaluate the benefit of preoperative chemoradiotherapy. After searching the database of Pubmed, CNKI, EMBASE, ESMO, The Cochrane Library databases, The American Society of Clinical Oncology and Clinical Trials...
September 28, 2016: Scientific Reports
X Duan, Y Cui, H Li, G Shi, B Wu, M Liu, D Chang, T Wang, Y Kong
BACKGROUND: Serum carcinoembryonic antigen (CEA) and the soluble fragment of cytokeratin 19 (CYFRA 21-1) are supposed to have a prognostic role in patients with nonsmall cell lung cancer (NSCLC) after surgery, but it has not been used as an adjunct to the tumor-node-metastasis (TNM) staging system to provide therapy options for patients with pathological Stage I NSCLC. This study was designed to investigate the effect of serum levels of CEA and CYFRA 21-1 before and after surgery on the prognosis of patients with Stage I NSCLC...
December 2015: Indian Journal of Cancer
Ryu Kanzaki, Hisamichi Naito, Kazuyoshi Kise, Kazuhiro Takara, Daisuke Eino, Masato Minami, Yasushi Shintani, Soichiro Funaki, Tomohiro Kawamura, Toru Kimura, Meinoshin Okumura, Nobuyuki Takakura
BACKGROUND: PSF1 (Partner of SLD Five 1) is an evolutionarily conserved DNA replication factor that is part of the GINS (Go, Ichi, Nii, and San) complex . The objective of this study was to evaluate the relationship between PSF1 expression and prognosis in patients with non-small cell lung cancer (NSCLC) treated with surgery following preoperative chemotherapy or chemoradiotherapy. METHODS: Sixty-nine patients with NSCLC treated with surgery following preoperative chemotherapy or chemoradiotherapy who did not achieve pathologic complete response were enrolled...
November 2016: Annals of Surgical Oncology
Yifan Zheng, Michael T Jaklitsch, Raphael Bueno
Locally advanced (stage IIIA) non-small cell lung cancer (NSCLC) is confined to the chest, but requires more than surgery to maximize cure. Therapy given preoperatively is termed neoadjuvant, whereas postoperative therapy is termed adjuvant. Trimodality therapy (chemotherapy, radiation, and surgery) has become the standard treatment regimen for resectable, locally advanced NSCLC. During the past 2 decades, several prospective, randomized, and nonrandomized studies have explored various regimens for preoperative treatment of NSCLC...
July 2016: Surgical Oncology Clinics of North America
Hongliang Ren, Wengui Xu, Jian You, Xiuyu Song, Hui Huang, Ning Zhao, Xiubao Ren, Xinwei Zhang
BACKGROUND: Lung cancer is the leading cause of cancer death in men and women in the world, more than one-half of cases are diagnosed at a advanced stage, and the overall 5-year survival rate for lung cancer is 18%. Lung cancer is divided into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). Approximately 80%-85% of cases are NSCLC which includes three main types: adenocarcinoma (40%), squamous cell carcinoma (SCC) (20%-30%), and large cell carcinoma (10%). Although therapies that target driver mutations in adenocarcinomas are showing some promise, they are proving ineffective in smoking-related SCC...
April 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
W Schreiner, W Dudek, S Lettmaier, S Gavrychenkova, R Rieker, R Fietkau, H Sirbu
The role of surgical lung resection following neo-adjuvant radio-chemotherapy (RCT) in patients with locally advanced non-small cell lung cancer (NSCLC) is yet not clearly defined. The aim of our study was to analyze the postoperative survival and to identify relevant prognostic factors. 46 patients underwent curative resections after neo-adjuvant RCT for locally advanced NSCLC (IIIA/IIIB) between February 2008 and February 2015. A retrospective data analysis regarding preoperative regression status, perioperative mortality, postoperative survival, patho-histological remission, relapse pattern and other prognostic factors was performed...
June 2016: Zentralblatt Für Chirurgie
Frederik Enders, Christoph Geisenberger, Christine Jungk, Justo Lorenzo Bermejo, Rolf Warta, Andreas von Deimling, Christel Herold-Mende, Andreas Unterberg
OBJECTIVE: Brain metastases (BMs) are the most common malignant brain tumors in adults. Despite multimodal treatment options such as microsurgery, radiotherapy and chemotherapy, prognosis still remains very poor. Non-small cell lung cancer (NSCLC) constitutes the most common source of brain metastases. In this study, prognostic factors in this patient population were identified through an in-depth analysis of clinical parameters of patients with BMs from NSCLC. PATIENTS AND METHODS: Clinical data of 114 NSCLC cancer patients who underwent surgery for BMs at the University Hospital Heidelberg were retrospectively reviewed for age, gender, type of treatment, time course of the disease, presence of neurologic symptoms, Karnofsky Performance Status (KPS), smoking history, presence of extracranial metastases at initial diagnosis of NSCLC, number, location and size of brain metastases...
March 2016: Clinical Neurology and Neurosurgery
Yoichi Ohtaki, Kimihiro Shimizu, Kyoichi Kaira, Toshiteru Nagashima, Kai Obayashi, Seshiru Nakazawa, Seiichi Kakegawa, Hitoshi Igai, Mitsuhiro Kamiyoshihara, Masahiko Nishiyama, Izumi Takeyoshi
PURPOSE: The aim of this study was to identify risk factors for recurrence in non-small cell lung cancer (NSCLC) patients with lymph node metastases after surgical resection. METHODS: We reviewed 66 consecutive patients with surgically resected NSCLC who had pathologically proven positive lymph nodes (pN1 or pN2). All patients underwent a preoperative 2-[(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) evaluation. We analyzed the recurrence-free survival (RFS) and recurrence-free proportion (RFP) according to the clinicopathological factors...
October 2016: Surgery Today
Se-Jun Park, Chong-Suh Lee, Sung-Soo Chung
BACKGROUND CONTEXT: A number of studies have reported favorable surgical results for metastatic spinal tumors from various solid tumors. However, there are few data available on metastatic spinal cord compression (MSCC) from lung cancer despite its considerable frequency. PURPOSE: The study aims to present the functional outcomes, survival time, and complications after surgical treatment for MSCC from non-small cell lung cancer (NSCLC). STUDY DESIGN/SETTING: This is a longitudinal observational study...
March 2016: Spine Journal: Official Journal of the North American Spine Society
Haitang Yang, Feng Yao, Yang Zhao, Heng Zhao
BACKGROUND: To assess the effect of preoperative neoadjuvant therapy on resectability, downstaging, and the prognosis in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). METHODS: Eighty-four patients who underwent resections after induction therapy [76 with neoadjuvant chemotherapy (CTx) and 8 with induction chemoradiotherapy (CRTx)] for clinically evident [larger than 1 cm on computed tomography (CT)] and pathologically confirmed ipsilateral N2 positive NSCLC (stage IIIA) between January 2009 and July 2013 were reviewed retrospectively...
September 2015: Journal of Thoracic Disease
Zuen Ren, Shijie Zhou, Zhidong Liu, Shaofa Xu
BACKGROUND: The efficacy of induction treatment plus surgery for improving postoperative survival in patients with non-small-cell lung cancer (NSCLC) in stages IIIA-N2 is controversial, especially compared with the combined chemotherapy and radiotherapy. We therefore performed a systematic review and meta-analysis of the published phase III randomized clinical trials (RCTs) to quantitatively evaluate the survival benefit of preoperative induction treatment vs. combined chemoradiotherapy...
August 2015: Journal of Thoracic Disease
Guangliang Qiang, Rui Xu, Jie Liu, Jue Yan, Yanyan Xu, Jinxi Di, Jiping Da, Chaoyang Liang, Bin Shi, Yongqing Guo, Deruo Liu
OBJECTIVE: To analyze the prognostic impact of preoperative (18)F-fluorodeoxyglucose (FDG) PET-CT on postoperative recurrence in patients with completely resected stage I non-small cell lung cancer (NSCLC). METHODS: The clinic data of 182 patients with stage I NSCLC who underwent (18)F-FDG PET-CT scan before surgical resection between June 2005 and June 2012 were reviewed retrospectively. There were 121 male and 61 female patients, with an average age of 68 years (range from 34 to 85 years)...
July 1, 2015: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
Heli Yang, Liang Dai, Pei Li, Luyan Shen, Wanpu Yan, Mengying Fan, Keneng Chen
BACKGROUND AND OBJECTIVE: It has still been controversial to treat N2-IIIa non-small cell lung cancer (NSCLC) patients by surgery or non-surgery. We retrospectively analysed the survival of 121 stage N2-IIIa NSCLC patients treated with surgery and explored their postoperatively long-term prognostic factors. METHODS: All of 1,290 patients in Beijing Cancer Hospital underwent resection by single-surgeon-team, among which 121 cases with stage N2-IIIa were enrolled in the study...
August 2015: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
Mara B Antonoff, Wayne L Hofstetter, Arlene M Correa, Jennifer M Bell, Boris Sepesi, David C Rice, Ara A Vaporciyan, Garrett L Walsh, Reza J Mehran, Stephen G Swisher, Bryan F Meyers
BACKGROUND: Management of superior sulcus non-small cell lung cancer (NSCLC) continues to evolve, with preoperative chemoradiotherapy (CXRT) followed by surgical intervention supported by several studies. Rates of pathologic complete response (pCR) have varied, and previous attempts to identify clinical predictors of pCR have been unsuccessful. We analyzed our experience with resected superior sulcus NSCLC to elucidate clinical features suggestive of pCR among patients after preoperative treatment...
January 2016: Annals of Thoracic Surgery
Pamela Samson, Aalok Patel, Traves D Crabtree, Daniel Morgensztern, Cliff G Robinson, Graham A Colditz, Saiama Waqar, Daniel Kreisel, A Sasha Krupnick, G Alexander Patterson, Stephen Broderick, Bryan F Meyers, Varun Puri
BACKGROUND: Improved survival of patients with early-stage non-small cell lung cancer (NSCLC) undergoing resection at high-volume centers has been reported. However, the effect of institution is unclear in stage IIIA NSCLC, where a variety of neoadjuvant and adjuvant therapies are used. METHODS: Treatment and outcomes data of clinical stage IIIA NSCLC patients undergoing resection as part of multimodality therapy was obtained from the National Cancer Database. Multivariable regression models were fitted to evaluate variables influencing 30-day mortality and overall survival...
November 2015: Annals of Thoracic Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"